FSSAI Ban on Ashwagandha Leaves: Crucial Safety Update

FSSAI Ban on Ashwagandha Leaves: Crucial Safety Update

The Food Safety and Standards Authority of India (FSSAI) recently issued a critical advisory regarding FSSAI Ashwagandha guidelines. This directive clarifies the permitted parts of Withania somnifera in food and health supplements. Consequently, the regulator now prohibits the use of leaves and their extracts in any form. Only roots and root-based extracts remain authorized for use in the Indian market.

New Standards for Nutraceuticals

The FSSAI specified these standards under the Food Safety and Standards Regulations of 2016. Specifically, Schedule IV of these regulations lists the botanicals permitted for health supplements and nutraceuticals. While roots have a long history of safe use, leaves fall outside the approved list. Therefore, manufacturers must adjust their formulations immediately to comply with these legal frameworks. For healthcare professionals advising patients on supplement safety, staying updated on clinical standards is essential—an area often covered in a Certification Course In Safe Prescribing.

Safety Concerns and Toxicological Risks

The Ministry of Ayush previously flagged safety concerns involving Ashwagandha leaves. Scientific studies indicate that leaves contain significantly higher levels of withanolides, such as Withaferin-A. These compounds link to adverse effects like liver toxicity and gastrointestinal distress. Furthermore, some research suggests potential neurotoxic effects from concentrated leaf extracts. Consequently, the restriction aims to protect consumers from these avoidable health risks.

Strict Compliance with FSSAI Ashwagandha Guidelines

Food Business Operators must ensure total adherence to these provisions. Any deviation from the root-only rule will attract legal action under the Food Safety and Standards Act of 2006. Additionally, State Food Safety Commissioners and Regional Directors have received instructions to maintain strict vigilance. They will monitor markets and initiate proceedings against non-compliant brands. This move ensures that only scientifically validated and safe plant parts reach the public. For those working in general practice, maintaining awareness of such regulatory updates is vital for patient safety and clinical excellence.

Frequently Asked Questions

Q1: Why did FSSAI ban the use of Ashwagandha leaves?

The ban exists because leaves contain higher concentrations of reactive withanolides like Withaferin-A. These compounds link to liver toxicity and other safety risks not associated with the root.

Q2: Are Ashwagandha root extracts still legal in India?

Yes, the FSSAI explicitly permits the use of Ashwagandha roots and their extracts. However, manufacturers must follow the prescribed limits set in the 2016 regulations.

Q3: What health risks do leaf extracts pose?

Studies link leaf extracts to liver toxicity and gastrointestinal issues. Furthermore, higher levels of certain compounds may pose neurotoxic risks to consumers.

References

1. FSSAI issues advisory on Ashwagandha use in food products; permits only rootsand extract – ETHealthworld
2. Food safety regulator directs manufacturers to use only Ashwagandha roots, bans leaves in food products – Telegraph India
3. FSSAI bans use of ashwagandha leaves in supplements, flags safety concerns – Business Standard

Disclaimer: This article was automatically generated from publicly available sources and is provided for informational and educational purposes only. OC Academy does not exercise editorial control or claim authorship over this content. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider and refer to current local and national clinical guidelines.